dermatitis

A biopharmaceutical company focused on the development of dermatology treatments saw a sharp drop after hours Thursday. What Happened: The clinical trial of Forte Biosciences (NASDAQ: FBRX) lead drug FB-401 failed to meet a statistical significance, the company said. Topline data from a Phase 2...

Edesa Biotech Inc's (NASDAQ: EDSA) EB01 has met a key interim study parameter as part of an adaptive Phase 2b trial evaluating EB01 as monotherapy for moderate to severe chronic Allergic Contact Dermatitis (ACD). Though blinded to treatment assignment, the study's...

Sanofi SA (ADR) (NYSE: SNY), is approaching a growth inflection point, according to Bank of America Merrill Lynch. The sell-side firm is projecting 6-percent earnings per share growth for the pharmaceutical company.  The Analyst Analyst Graham Parry upgraded Sanofi from Neutral to Buy and...